HomeAI · summaries
Storia in 6 fonti
FDA approves Orca Bio’s T cell therapy for blood cancer patients
The FDA approved a T-cell therapy from Orca Bio that reduces the risk of a debilitating immune reaction in patients with blood cancers undergoing stem cell transplants.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
morningstar.com
Orca Bio’s TREGZI™ Receives U.S. FDA Approval as First and Only Precision-Engineered Cell Therapy for Allogeneic Transplant in Adults with…
Orca Bio’s TREGZI™ Receives U.S. FDA Approval as First and Only Precision-Engineered Cell Therapy for Allogeneic Transplant in Adults with Hematological Malignancies
- ·
healio.com
FDA approves Tregzi as first Treg cell therapy for allogenic transplant in blood cancers
The FDA has approved an allogeneic regulatory T cell immunotherapy for use in matched-donor hematopoietic stem cell transplantation in patients with blood cancers, to improve…
